Valuation: Omeros Corporation

Market Cap 74Cr 65Cr 60Cr 55Cr 105.19Cr 7.09TCr 106.95Cr 717.26Cr 281.34Cr 3.49TCr 279.06Cr 273Cr 12TCr P/E 2026 *
31.1x
P/E 2027 * -36.7x
Enterprise Value 74Cr 65Cr 60Cr 55Cr 105.19Cr 7.09TCr 106.95Cr 717.26Cr 281.34Cr 3.49TCr 279.06Cr 273Cr 12TCr EV / Sales 2026 *
11x
EV / Sales 2027 * 5.19x
Free-Float
96.44%
Yield 2026 *
-
Yield 2027 * -
1 day+0.10%
1 week-0.58%
Current month+8.10%
1 month+0.78%
3 months-10.53%
6 months-19.81%
Current year-40.15%
1 week 9.25
Extreme 9.25
10.68
1 month 6.7
Extreme 6.7023
10.83
Current year 6.7
Extreme 6.7023
17.63
1 year 3.34
Extreme 3.34
17.65
3 years 0.92
Extreme 0.92
17.65
5 years 0.92
Extreme 0.92
17.65
10 years 0.92
Extreme 0.92
27.09
Manager TitleAgeSince
Chief Executive Officer 67 16/06/1994
Director of Finance/CFO 62 30/06/2024
Chief Tech/Sci/R&D Officer 70 01/11/2019
Director TitleAgeSince
Chairman 67 16/06/1994
Director/Board Member 86 01/01/1995
Director/Board Member 72 01/01/1995
Date Insider Type Main position Quantity % Market Cap.
18/06Free

Director

15,000 0.0207%
18/06Free

Director

15,000 0.0207%
18/06Free

Director

15,000 0.0207%
Change 5-day change 1-year change 3-year change Capi.($)
+0.10%-0.58%+197.11%+90.02% 74Cr
-4.14%-7.44%+64.26%+119.36% 5.7TCr
+1.84%+1.65%+76.90%+95.68% 5.36TCr
-2.24%+3.65%+19.60%+466.72% 2.56TCr
-1.60%-2.60%-19.69%-14.84% 2.35TCr
+2.43%+5.86%+46.56%+0.42% 1.94TCr
-3.19%-0.29%+36.24%-27.32% 1.81TCr
-6.84%+2.18%+203.03%+348.11% 1.65TCr
+8.74%+10.46%+47.66% - 1.41TCr
-1.05%+1.75%+25.08%+196.28% 1.44TCr
Average -0.59%+2.11%+69.68%+141.60% 2.43TCr
Weighted average by Cap. -1.02%+0.33%+57.23%+138.40%

Financials

2026 *2027 *
Net sales 6.78Cr 5.94Cr 5.48Cr 5.06Cr 9.6Cr 646.93Cr 9.76Cr 65Cr 26Cr 318.66Cr 25Cr 25Cr 1.1TCr 14Cr 13Cr 12Cr 11Cr 20Cr 1.36TCr 21Cr 138.09Cr 54Cr 672.25Cr 54Cr 53Cr 2.31TCr
Net income 2.12Cr 1.86Cr 1.72Cr 1.58Cr 3Cr 202.5Cr 3.06Cr 20Cr 8.04Cr 100Cr 7.97Cr 7.8Cr 343.28Cr -4.72Cr -4.14Cr -3.82Cr -3.53Cr -6.69Cr -450.62Cr -6.8Cr -46Cr -18Cr -221.97Cr -18Cr -17Cr -763.9Cr
Net Debt - -
Logo Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions.
Employees
175
Date Price Change Volume
10/26/10 $10.28 +0.10% 10,90,243
09/26/09 $10.27 +0.29% 8,75,884
08/26/08 $10.24 -0.87% 14,96,609
07/26/07 $10.33 -0.10% 12,36,226
06/26/06 $10.34 +11.42% 17,45,449
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
10.27USD
Average target price
33.00USD
Spread / Average Target
+221.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OMER Stock